Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, APRIL 27, 2026
08:00 - 09:00
REGISTRATION AND MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:35
LATEST ADVANCEMENTS IN mRNA FORMULATION AND DELIVERY TECHNOLOGIES
Pintu Kanjilal
Strand Therapeutics

Pintu Kanjilal

Strand Therapeutics

  • Emphasizing the need for robust delivery platforms enabling clinical mRNA therapies
  • Enumerating delivery strategies applied to achieve efficient, reliable mRNA transport
  • Affirming LNPs as preferred vehicles for mRNA drug products in development and commercialization
  • Summarizing key learnings from recent LNP programs spanning formulation and safety
09:35 - 09:40
Q&A SESSION ON ADVANCES IN mRNA FORMULATION AND DELIVERY
09:40 - 10:05
MECHANISMS OF ENDOSOMAL ESCAPE AND INTRACELLULAR DELIVERY MEDIATED BY LIPID NANOPARTICLE COMPONENTS
Ismail Hafez
Ionis Pharmaceuticals Inc.

Ismail Hafez

Ionis Pharmaceuticals Inc.

  • Establishing how lipid nanoparticles enable intracellular delivery of mRNA via endosomal pathways
  • Differentiating the roles of ionizable, helper, and sterol lipids in endosomal rupture and mRNA release
  • Evaluating revised models of ionizable lipid-mediated endosomal escape against current evidence
10:05 - 10:10
Q&A SESSION ON LNP ENDOSOMAL ESCAPE AND DELIVERY MECHANISMS
10:10 - 10:35
NANOPRIMER TECHNOLOGY FOR ENHANCED EFFICACY OF INTRAVENOUSLY ADMINISTERED VACCINES
Julie Devalliere
Nanobiotix

Julie Devalliere

Nanobiotix

  • Reducing hepatic clearance by transiently occupying phagocyte cells that clear nanoparticles
  • Pre-treating with Nanoprimer to increase IV bioavailability during the therapeutic activity window
  • Eliciting stronger CD8⁺ T cell priming and IFN-γ responses across mRNA and peptide vaccines
10:35 - 10:40
Q&A SESSION ON NANOPRIMER TO BOOST IV VACCINE IMMUNOGENICITY
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON AI/ML-DRIVEN ADVANCEMENTS IN RNA THERAPEUTICS MANUFACTURING
Speaker ImageSpeaker ImageSpeaker Image
  • Discussing design for manufacturability using AI to generate mRNA sequences meeting performance and CMC constraints
  • Connecting production line and logistics data into unified pipelines that reliably power AI driven manufacturing decisions
  • Clarifying patent strategy and inventor attribution for AI designed nucleic acids and RNA therapeutics
  • Highlighting AI enabled manufacturing innovation including containerized vaccine production and RNA based diagnostics scaling insights

| Gardn Biosciences

| Hongene Biotech Corporation

| Lathrop GPM LLP

| Harman PhD Consulting

11:30 - 11:55
HIXCAP™: CAP ANALOGS RATIONALLY DESIGNED FOR IMMUNE EVASION AND TRANSLATIONAL EFFICIENCY IN mRNA THERAPEUTICS
Tao Jiang
Hongene Biotech Corporation

Tao Jiang

Hongene Biotech Corporation

  • Structuring novel 5′ cap analogs to improve translation in immunologically active environments
  • Counteracting IFIT1-mediated suppression to enhance mRNA output under inflammatory conditions
  • Positioning HiXCap™ E2 for trials after efficacy in JAWS II cells, LPS mice, and case studies
11:55 - 12:00
Q&A SESSION ON 5' CAP ANALOGS FOR mRNA TRANSLATION
12:00 - 12:25
PROBLEMS WITH LONG mRNA SYNTHESIS? – CONGESTION ON THE DNA TEMPLATE GENERATES RNA FRAGMENTS VIA POLYMERASE BUMPING
Craig Martin
University of Massachusetts

Craig Martin

University of Massachusetts

  • Investigating polymerase bumping on crowded DNA templates that generate truncated RNA
  • Quantifying how polymerase density on DNA governs collision frequency and fragment yield
  • Preventing bumping through co-tethered transcription to restore full-length mRNA output
12:25 - 12:30
Q&A SESSION ON POLYMERASE BUMPING IN mRNA SYNTHESIS
12:30 - 13:30
NETWORKING LUNCH & VISITING THE mRNA EXHIBITION
13:30 - 13:55
PHASE-APPROPRIATE CMC STRATEGIES FOR DEVELOPMENT OF RNA-BASED THERAPIES FOR CONCURRENT APPROVALS IN US AND EU
Rajiv Gangurde
Parexel

Rajiv Gangurde

Parexel

  • Aligning early and late-stage CMC plans across diverse RNA therapies to de-risk scale-up
  • Sequencing CMC work to stay off the critical path while regulatory guidance remains limited
  • Navigating US and EU requirements to build a global approval strategy for RNA-based therapies
13:55 - 14:00
Q&A SESSION ON PHASE-APPROPRIATE CMC FOR RNA THERAPIES
14:00 - 14:25
RISK AND REWARD OF ACCELERATING mRNA THERAPEUTICS FROM DEVELOPMENT TO THE CLINIC
Marieke Zhao
Syner-G

Marieke Zhao

Syner-G

  • Identifying bottlenecks that constrain mRNA development timelines from lab to clinic
  • Defining regulatory requirements for starting materials used in mRNA manufacturing supply chains
  • Examining a case study linking starting material quality to downstream mRNA quality attributes
14:25 - 14:30
Q&A SESSION ON ACCELERATING mRNA THERAPEUTICS TO CLINIC
14:30 - 14:55
MASS PHOTOMETRY AS A NEXT-GENERATION PLATFORM FOR MULTI-ATTRIBUTE RNA THERAPEUTIC ANALYTICS
Matthew J Ranaghan
Refeyn

Matthew J Ranaghan

Refeyn

  • Characterizing native m/saRNA length, purity, aggregation and degradation in one readout
  • Measuring integrity and purity of up to 10 kb m/saRNA with under 5% error from ng of material
  • Resolving dsRNA impurity profiles directly in heterogeneous mRNA samples for decisions
14:55 - 15:00
Q&A SESSION ON MASS PHOTOMETRY FOR MULTI-ATTRIBUTE RNA ANALYTICS
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 15:55
KEY CMC CONSIDERATIONS FOR mRNA THERAPEUTICS TOWARDS IND APPROVAL
Xijun Piao
CATUG Biotechnology

Xijun Piao

CATUG Biotechnology

  • Deciphering end-to-end mRNA therapeutic workflows that underpin CMC readiness for IND
  • Prioritizing key CMC considerations across materials, process development, and controls for IND
  • Showcasing CATUG Biotechnology’s one-stop CMC service to streamline development toward filing
15:55 - 16:00
Q&A SESSION ON KEY CMC STEPS TOWARDS IND APPROVAL
16:00 - 16:25
GENERATIVE DESIGN OF COMPLETE THERAPEUTIC mRNA MOLECULES
Aidan Riley
Gardn Biosciences

Aidan Riley

Gardn Biosciences

  • Integrating 5′ UTR, coding sequence, and 3′ UTR in one pass to optimize full-length mRNA
  • Showing optimized linear mRNA constructs outperform circular RNA in expression and in vivo utility
  • Achieving cell type specificity, lower immunogenicity, and manufacturability via end-to-end design
16:25 - 16:30
Q&A SESSION ON GENERATIVE DESIGN OF THERAPEUTIC mRNA
16:30 - 16:55
RNA THERAPEUTICS: MULTI-MODALITY POTENTIAL FROM GENE SILENCING THROUGH THERAPEUTICS
Anis H Khimani
ZeptoMetrix Corporation

Anis H Khimani

ZeptoMetrix Corporation

  • Tracing the shift from transcriptional paradigms to therapeutic applications with context
  • Surveying a broad pipeline spanning therapeutic areas and modalities across RNA medicines
  • Anticipating challenges and future opportunities for multi modal RNA therapeutics
16:55 - 17:00
Q&A SESSION ON MULTI-MODAL RNA THERAPEUTICS
17:00 - 17:25
A NOVEL circRNA VACCINE FOR CHIKUNGUNYA
Daniel L. Kiss
Houston Methodist Research Institute

Daniel L. Kiss

Houston Methodist Research Institute

  • Benchmarking circRNA versus linear mRNA in lethal challenge, showing stronger protection
  • Verifying circRNA sequences at RNA level with extensive validation to confirm construct integrity
  • Refining antigen designs through mutational scanning to improve circRNA vaccine performance
17:25 - 17:30
Q&A SESSION ON circRNA VACCINE DESIGN FOR CHIKUNGUNYA
17:30 - 18:30
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, APRIL 28, 2026
08:30 - 09:00
MORNING REFRESHMENTS
09:00 - 09:10
OPENING ADDRESS
09:10 - 09:40
RESERVED PRESENTATION
09:40 - 10:05
OBTAINING BROAD PATENTS IN BIOTECH
Laura A Labeots
Lathrop GPM LLP

Laura A Labeots

Lathrop GPM LLP

  • Interpreting Amgen v. Sanofi to clarify enablement under 35 USC 112(a) for biotech
  • Summarising core enablement principles that shape biological drug and antibody claim scope
  • Drafting broad, defensible claims using practical strategies and specification support
10:05 - 10:10
Q&A SESSION ON BROAD BIOTECH PATENT CLAIM STRATEGIES
10:10 - 10:35
ENGINEERED EXTRACELLULAR VESICLES ENGINEERED WITH mRNA FOR TREATMENT OF DEGENERATIVE DISC DISEASE
Wenchun Qu
Mayo Clinic

Wenchun Qu

Mayo Clinic

  • Highlighting potent immunomodulatory effects of mRNA-engineered extracellular vesicles (EV)
  • Addressing disc regeneration using mRNA-based therapeutics to restore structure and function
  • Contextualizing EV design and delivery variables that influence targeting to disc tissues
10:35 - 10:40
Q&A SESSION ON ENGINEERED EV FOR mRNA THERAPEUTICS
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:25
ENHANCING mRNA–LNP DOWNSTREAM PROCESSING VIA SINGLE-PASS TANGENTIAL FLOW FILTRATION (SPTFF)
Angel Lorenzo
Cytiva

Angel Lorenzo

Cytiva

  • Framing single-pass tangential flow filtration fundamentals for mRNA–LNP downstream workflows
  • Dissecting LNP anatomy and process CQAs that govern purification performance and consistency
  • Relating SPTFF characterisation results to saRNA-in-LNP potency and drug product quality
11:25 - 11:30
Q&A SESSION ON SPTFF FOR mRNA–LNP DOWNSTREAM PROCESSING
11:30 - 11:55
ANTISENSE BASED MICROBIAL TARGETING VIA ANTIBODY-NANOPARTICLE CONJUGATES
Brandon Armstead
Brown University Health

Brandon Armstead

Brown University Health

  • Formulating antibody-targeted nanoparticles to deliver antisense oligos to septic pathogens
  • Profiling pathogen gene targets from whole-blood diagnostics to guide selective depletion plans
  • Conjugating surface antibodies to improve targeting and delivery of gene-silencing cargo
11:55 - 12:00
Q&A SESSION ON ANTISENSE NANOPARTICLE SEPSIS TARGETING
12:00 - 12:25
A NOVEL CIRCULAR RNA PLATFORM THAT PREFERENTIALLY TARGETS PROTEIN PRODUCING CELLS
Peter Weinstein
Circurna

Peter Weinstein

Circurna

  • Stabilizing thermostable ciRNA™ delivered by microneedle patches for dermal protein output
  • Administering ciRNA™ to dermis cells that drive in vivo protein production for therapy response
  • Sustaining protein expression for over a week, enabling one or two doses to reach effect
  • Extending two-dose vaccine efficacy into programs for cancer, fibrosis, autoimmune disease
12:25 - 12:30
Q&A SESSION ON ciRNA PLATFORM TARGETING PROTEIN-PRODUCING DERMAL CELLS
12:30 - 13:30
NETWORKING LUNCH & VISITING THE mRNA EXHIBITION
13:30 - 13:55
REVSELECT™ AI-POWERED 5′ UTR OPTIMIZATION DRIVING 65% HIGHER PROTEIN EXPRESSION AND ACCELERATED PATHWAYS FOR PERSONALIZED mRNA THERAPEUTICS
Molly McGlaughlin
Revolution Biomanufacturing Inc.

Molly McGlaughlin

Revolution Biomanufacturing Inc.

  • Optimizing 5′ and 3′ UTRs with AI models to refine ribosome loading and translation outcomes
  • Leveraging pretrained language models and structural features to predict translational efficiency
  • Demonstrating 65% gains in protein expression using validated UTR designs across models
  • Uncovering novel IRES elements with improved precision to advance personalized mRNA use
13:55 - 14:00
Q&A SESSION ON AI-POWERED UTR OPTIMIZATION FOR mRNA
14:00 - 14:25
NOVEL APPROACH TO IDENTIFY BIOMARKERS FOR mRNA-BASED THERAPEUTICS AND VACCINES
Fredrik Sundberg
Standard BioTools

Fredrik Sundberg

Standard BioTools

  • Confronting gaps in safety and efficacy biomarkers for mRNA, siRNA and miRNA modalities
  • Advancing analytics to yield biologically relevant data for decisions and clinical outcome prediction
  • Demonstrating autoantibody biomarkers via post-COVID cohorts and vaccine development case studies
14:25 - 14:30
Q&A SESSION ON BIOMARKERS FOR mRNA THERAPEUTICS AND VACCINES
14:30 - 14:55
IMPURITY CHARACTERIZATION AND CONTROL DURING mRNA PRODUCTION
Kok-Seong Lim
Independent Consultant

Kok-Seong Lim

Independent Consultant

  • Pinpointing key impurity sources in mRNA production, including dsRNA and mRNA–lipid adducts
  • Implementing analytical methods for accurate detection and quantification of impurities
  • Minimizing impurities via practical steps, in-process controls, and post-purification optimization
14:55 - 15:00
Q&A SESSION ON IMPURITY CONTROL IN mRNA PRODUCTION
15:00 - 15:15
FEEDBACK & RAFFLE DRAW
15:15 - 15:30
CLOSING REMARKS

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.